The initial public offering (IPO) of Corona Remedies Limited has officially opened for subscription today, Monday, December 8, 2025. The Ahmedabad-based pharmaceutical company is looking to raise ₹655.37 crore through this mainboard issue. The IPO will remain open for bidding for three days, concluding on Wednesday, December 10, 2025.
Corona Remedies is a key player in the Indian pharmaceutical market, specializing in women’s healthcare, cardiology, and pain management. Unlike many recent IPOs, this issue is entirely an Offer for Sale (OFS), meaning the company will not receive any fresh capital from the proceeds. Instead, existing shareholders and promoters are selling their stakes.
Market analysts and investors are closely watching this IPO due to the company’s strong financial track record and double-digit profit margins. Early trends from the grey market suggest a healthy appetite for the shares, with a significant premium already being commanded before the listing.
Price Band and Lot Size Details
The company has fixed the price band for the issue at ₹1,008 to ₹1,062 per equity share. Retail investors can bid for a minimum of one lot, which comprises 14 shares. At the upper end of the price band, the minimum investment required for a retail applicant is ₹14,868.
For High Net-Worth Individuals (HNIs) and Non-Institutional Investors (NIIs), the investment thresholds are higher. The minimum lot size for small HNIs (sNII) is 14 lots (196 shares), requiring an investment of ₹2,08,152. Big HNIs (bNII) must apply for at least 68 lots (952 shares), amounting to over ₹10 lakh.
The issue is structured to allocate 50% of the net offer to Qualified Institutional Buyers (QIBs), 15% to NIIs, and 35% to Retail Individual Investors. This distribution ensures that retail participants have a fair chance at allotment.
Grey Market Premium (GMP) Signals Strong Listing
The Grey Market Premium (GMP) for Corona Remedies has been trending upwards, signaling positive sentiment. As of the opening day, the GMP stands at approximately ₹290 to ₹307 per share. This premium indicates that the shares are trading at roughly 27% to 29% higher than the issue price in the unofficial market.
If these trends hold until the listing day, the stock could debut at around ₹1,352 per share. While GMP is not an official indicator, it often reflects the demand-supply dynamics and investor confidence in the IPO.
The consistent GMP suggests that investors are valuing the company’s growth potential and its position as one of the fastest-growing pharmaceutical companies in India.
Subscription Status: Day 1 Trends
The subscription window opened at 10:00 AM today. Early data indicates a steady start from retail investors. By the early hours of Day 1, the issue had been subscribed around 0.11 times (11%) overall.
Analysts expect the subscription numbers to pick up significantly by the afternoon and over the next two days. Institutional investors usually place their big bids on the final day, so the current figures are largely driven by retail and HNI interest.
Investors are advised to keep an eye on the subscription levels in the QIB category, as strong institutional interest is often a good sign of long-term value.
Company Financials and Growth Outlook
Corona Remedies has demonstrated robust financial health leading up to the IPO. For the fiscal year 2025, the company reported a revenue of ₹1,202 crore, marking an 18% increase from the previous year. More impressively, the Profit After Tax (PAT) surged by 65% to ₹149 crore.
The company boasts strong return ratios, with a Return on Equity (ROE) of 27.5% and a Return on Capital Employed (ROCE) of 41.3%. These figures are competitive when compared to listed peers in the pharma sector.
Support Our Journalism
The company’s focus on chronic and sub-chronic therapies, which account for over 70% of its domestic sales, provides a stable revenue stream. With two manufacturing facilities in Gujarat and a wide distribution network, the company is well-positioned for future expansion.
Important Dates for Investors
- IPO Closing Date: Wednesday, December 10, 2025
- Basis of Allotment: Thursday, December 11, 2025
- Refunds/Unblocking of Funds: Friday, December 12, 2025
- Credit of Shares: Friday, December 12, 2025
- Listing Date: Monday, December 15, 2025
Investors should mark these dates to track their application status. The allotment status will be available on the website of the registrar, Bigshare Services Pvt. Ltd..
Related Disclaimer: The information provided in this article is for educational purposes only. It does not constitute financial advice. GMP values are unofficial and subject to change. Investors should consult a certified financial advisor before making investment decisions.
About the Author
📢 Click here for instant updates:
📲 Join us on WhatsApp
